Q-omics provides the consensus-scored COPS4 profile across patient tissues and cancer cell-line models. COPS4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, COPS4 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, COPS4 protein abundance shows 22,928 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, THCA, and HNSC as cancer lineages where COPS4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for COPS4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes COPS4 survival associations across molecular data types. COPS4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible COPS4 RNA expression–survival associations across cancer types. High COPS4 expression shows unfavorable associations in LIHC and UVM, but favorable associations in KIRC, COAD, READ and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for COPS4 RNA expression.
This table summarizes COPS4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 8. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for COPS4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. COPS4 shows lower tumor expression in THCA, BLCA, KICH, KIRP and KIRC and higher tumor expression in LIHC. The THCA box plot shows higher COPS4 RNA expression in normal versus tumor tissue (log2 FC = −0.658, t-test p < 0.001).
This table shows molecular features associated with COPS4 in patient tissues and cancer cell lines. In patient samples, COPS4 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, COPS4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
